BioSpace News Archive

PharmaCyte Biotech, Inc. today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company’s common stock

Cyclerion Therapeutics, Inc. today announced participation in the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 25-26, 2021.

Huntington Hospital has opened the Helen and Will Webster Heart & Vascular Center, the most comprehensive and innovative facility for cardiac care in the San Gabriel Valley.

Immunexpress today announced that the SeptiCyte® RAPID test will be evaluated in the diagnosis of paediatric sepsis in Queensland children.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, “Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson’s Disease,” in the European Molecular Biology Organization Journal.

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting and hosting a booth this week at the 13th Annual Next Generation Dx Summit on Aug 24-26 in Washington, D.C.

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authorities they did not need a third, booster dose of the vaccine as their protection remained high, six months after getting a second dose.

SOHM, Inc., a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories announced that the Company has finished its due diligence for its previously announced proposed acquisition of a leading Southern California based pharmaceutical company.

This new patent continues to expand the broad reach of Relay’s intellectual property portfolio for its diagnostics and analysis platforms in the rapidly growing IoT (“internet-of-things”) healthcare market.